Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04291885|
Recruitment Status : Recruiting
First Posted : March 2, 2020
Last Update Posted : November 20, 2020
|Condition or disease||Intervention/treatment||Phase|
|Merkel Cell Carcinoma Merkel Cell Carcinoma, Stage I Merkel Cell Carcinoma, Stage II Merkel Cell Carcinoma, Stage III Neuroendocrine Tumors Carcinoma Neuroendocrine Skin||Drug: Avelumab Drug: Placebo||Phase 2|
The I-MAT trial is a phase II, prospective, randomised, placebo-controlled, multi-institutional trial for patients with stage I-III Merkel cell carcinoma (MCC). Treatment will be avelumab vs placebo for 6 months duration. The primary aim of the I-MAT trial is to develop an effective, well-tolerated adjuvant immunotherapy regimen for patients with stage I-III MCC, post a range of definitive loco-regional treatment options.
Biological differences for Merkel Cell Polyomavirus (MCPyV)-positive versus MCPyV-negative patients in the adjuvant setting will be explored.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||132 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma|
|Actual Study Start Date :||October 8, 2020|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2028|
6 months of Avelumab at a dose of 800mg as a 60-minute IV infusion once every 2 weeks (13 doses)
Avelumab IV infusion
Placebo Comparator: Placebo
6 months of Placebo as a 60-minute IV infusion once every 2 weeks (13 doses)
Placebo IV infusion
- Recurrence-free survival (RFS) [ Time Frame: 24 Months ]RFS, the primary endpoint, is anticipated to be analysed over an average planned follow-up of 3.5 years per participant. An analysis of RFS at the 24 month time point of follow-up per participant will also be conducted as it is anticipated that the minimum follow-up per patient will be 24 months and the sample size rationale utilises RFS rates at 24 months in historical controls. RFS is defined as the time from treatment initiation until the first date of any signs or symptoms of recurrence of tumour.
- Overall survival (OS) [ Time Frame: 24 Months ]OS rates at specific landmark timepoints of 12 and 24 months. OS is defined as the time from treatment initiation to the date of death due to any cause.
- Disease-specific survival (DSS) [ Time Frame: 24 Months ]DSS is the percentage of participants who have not died from Merkel Cell Carcinoma at 24 months from treatment initiation.
- Rate of loco-regional failure free survival (LRFFS) [ Time Frame: 24 Months ]Rate of loco-regional failure free survival (LRFFS) is defined as the time from treatment initiation to the first recurrence of the loco-regional tumour.
- Distant metastasis-free survival (DMFS) [ Time Frame: 24 Months ]DMFS is defined as the time from treatment initiation to the first evidence of distant metastatic disease.
- Treatment toxicity and tolerability as assessed by NCI CTCAE v5.0 [ Time Frame: 24 Months ]Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed as per NCI CTCAE v5.0, including immune-related adverse events.
- Patient-reported quality of life (QoL) as assessed by FACT-M questionnaire [ Time Frame: 24 Months ]FACT-M form (version 4) will be utilised. This will include patient-reported questions relating to physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and additional patient concerns which are measured from 0-4 (Not at all - Very Much).
- Rate of Merkel cell polyomavirus positivity in stage I-III Merkel cell carcinoma [ Time Frame: 24 Months ]To identify Merkel cell polyomavirus MCPyV virus status. To correlate viral aetiology-rate of Merkel cell polyomavirus (MCPyV) positivity in pathology specimens in stage I-III Merkel cell carcinoma- with outcome following adjuvant treatment.
- Correlating whole exome sequencing (WES) and ribonucleic acid (RNA) expression with immunotherapy response and outcomes in early stage MCC [ Time Frame: 24 Months ]To evaluate the relationship between somatic mutations in cancer genes or the total mutation burden of the cancer with immunotherapy response and outcome following adjuvant therapy.
- Correlating immune infiltrates by multiplex immunohistochemistry (IHC) with survival endpoints [ Time Frame: 24 Months ]To address whether immune infiltrates and PD-L1 expression are associated with survival endpoints.
- Utility of circulating biomarkers in predicting recurrence in early stage MCC [ Time Frame: 24 Months ]To identify predictive biomarkers for response and resistance to immunotherapy in patients with stage I-III MCC using archival tissue and peripheral blood.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291885
|Contact: Narelle Williamsemail@example.com|
|Australia, New South Wales|
|Chris O'Brien Lifehouse||Not yet recruiting|
|Sydney, New South Wales, Australia, 2050|
|Contact: Dr Jenny Lee 0293831014 Jenny.Lee@lh.org.au|
|Principal Investigator: Dr Jenny Lee|
|Melanoma Institute Australia||Not yet recruiting|
|Sydney, New South Wales, Australia, 2065|
|Contact: Prof Georgina Long 0299117336 Georgina.Long@sydney.edu.au|
|Principal Investigator: Prof Georgina Long|
|Royal North Shore Hospital||Recruiting|
|Sydney, New South Wales, Australia, 2065|
|Contact: A/Prof Alexander Guminski 0299265020 Alexander.Guminski@health.nsw.gov.au|
|Principal Investigator: A/Prof Alexander Guminski|
|Sydney, New South Wales, Australia, 2145|
|Contact: Prof Michael Veness 0288905200 Michael.Veness@health.nsw.gov.au|
|Principal Investigator: Prof Michael Veness|
|Calvary Mater Hospital||Recruiting|
|Sydney, New South Wales, Australia, 2298|
|Contact: Dr Ina Nordman 0240143190 Ina.Nordman@calvarymater.org.au|
|Principal Investigator: Dr Ina Nordman|
|Royal Brisbane and Woman's Hospital||Not yet recruiting|
|Brisbane, Queensland, Australia, 4029|
|Contact: Dr Melissa Eastgate 0736469917 Melissa.Eastgate@health.qld.gov.au|
|Principal Investigator: Dr Melissa Eastgate|
|Townsville, Queensland, Australia|
|Contact: Dr Madhavi Chilkuri 0744331801 Madhavi.Chilkuri@health.qld.gov.au|
|Principal Investigator: Dr Madhavi Chilkuri|
|Princess Alexandra Hospital||Recruiting|
|Woolloongabba, Queensland, Australia, 4102|
|Contact: A/Prof Victoria Atkinson 0731762111 firstname.lastname@example.org|
|Principal Investigator: Dr Wen Xu|
|Principal Investigator: A/Professor Victoria Atkinson|
|Australia, South Australia|
|Royal Adelaide Hospital||Recruiting|
|Adelaide, South Australia, Australia, 5000|
|Contact: Prof Michael Brown 0883027827 MichaelP.Brown@sa.gov.au|
|Principal Investigator: Prof Michael Brown|
|Melbourne, Victoria, Australia, 3000|
|Contact: Prof Mark Shackleton 0390763129 email@example.com|
|Principal Investigator: Prof Mark Shackleton|
|Peter MacCallum Cancer Centre||Recruiting|
|Melbourne, Victoria, Australia, 3000|
|Contact: A/Prof Shahneen Sandhu 0385595000 Shahneen.Sandhu@petermac.org|
|Principal Investigator: A/Prof Shahneen Sandhu|
|Australia, Western Australia|
|Affinity Oncology||Not yet recruiting|
|Perth, Western Australia, Australia, 6150|
|Contact: A/Prof Adnan Khattak 08 6152 2222 Muhammad.Khattak@health.wa.gov.au|
|Principal Investigator: A/Prof Muhammad Adnan Khattak|
|Study Chair:||Wen Xu, MBBS, FRACP||Princess Alexandra Hospital|